
Expand Your Perspective with Genetics
Doğru Test Doğru Karar
With nearly 20 years of experience, a broad test portfolio, and an innovative perspective, we provide tailored diagnostic and treatment solutions for every patient.
Our tests, designed to address individualized needs, provide guidance in the development of personalized treatment protocols.
Providing reliable and guiding clinical support through pioneering approaches in high-quality precision diagnostic solutions, utilizing CE-IVD marked kits and referenced international bioinformatics analysis systems.
● Our tests are subject to CAP and GENQA External Quality Control.
● We hold ISO:15189 accreditation in accordance with Medical Laboratory Standards.
Our laboratory’s genetic analyses enhance the diagnostic process by providing dependable and guiding clinical insights backed by a team of specialists.

For all solid tumors, we evaluate the tumor's genetic profile using molecular and cytogenetic methods (NGS, dPCR, RT-PCR, and FISH) to support targeted and personalized treatment.

As Nesiller Genetic, we contribute to both carrier screening and infertility assessment processes by identifying hereditary genetic risks in couples planning to conceive, through our carrier and reproductive genetics panels.

We enable the selection of healthy embryos through pre-transfer embryo screening during the IVF process and minimize genetic risks using innovative PGT methods that meet international standards.

We provide personalized diagnostic and treatment solutions for clinically complex cases with overlapping phenotypes, diagnostic challenges, familial risk assessments, and rare complex diseases through WGS, WES, CNV analysis, and mitochondrial DNA (mtDNA) analysis.

Kanda dolaşan tümör DNA’sını (ctDNA) görüntüleme cihazlarından aylar önce tespit eden, FDA onaylı ve kişiye özel moleküler temelli bir kanser takip testidir.

Developed for individuals with a family history of cancer, those seeking to understand their cancer risk, or patients aiming to define treatment options following diagnosis.

FoundationOne Heme is a comprehensive genomic profiling (CGP) test that combines DNA and RNA sequencing for patients with hematologic malignancies and solid tumors.

Pharmacogenetic testing enhances drug effectiveness and supports treatment by personalizing dosage requirements and minimizing potential adverse effects.

Minimal Residual Disease (MRD) testing can detect cancer recurrence months earlier than conventional imaging technologies by analyzing circulating tumor DNA (ctDNA). It is an FDA-approved, personalized molecular assay for cancer monitoring.

Non-Invasive Prenatal Testing (NIPT) is a screening test that analyzes cell-free fetal DNA (cffDNA) in maternal blood from the 9th week of pregnancy onward.

Identifies genetic risk factors associated with Alzheimer’s disease, Parkinson’s disease, and dementia. This panel enables early detection and guides personalized treatment and planning.
Founder & General Manager
“Genetic testing helps my colleagues understand their patients more accurately, monitor them with a personalized and holistic approach, and tailor treatment decisions more effectively.”
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, Şişli / Istanbul
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00
The content provided on this site is intended for informational purposes only and is not a substitute for professional medical advice or diagnosis. Always seek the advice of a qualified healthcare provider for any medical evaluation, diagnosis, or treatment.
All rights reserved © 2026. Explicit Consent Statement | Last Updated: 27.04.2026 14:00 / mowaffak@hotmail.com
I acknowledge that I have read and understood the Privacy Notice provided by Nesiller Genetic Laboratories, acting as the data controller. The Privacy Notice clearly and comprehensively explains the identity of the data controller, the categories of personal data to be processed, the purposes of processing, the recipient groups to whom personal data may be transferred, the methods and legal grounds for data collection, and my rights as a data subject. I have also been informed that more detailed information is available in the Personal Data Retention and Destruction Policy and in the records maintained within the VERBIS system at the address indicated.
In addition to the matters described in the Privacy Notice, I freely give my explicit consent, with full awareness of the meaning, legal consequences, and potential future implications of this declaration, to the processing of my name, surname, email address, telephone number, company name, country, city, and address solely for the purposes of product and service promotions, gifts, discounts, new opportunities and special offers, announcements, advertisements, campaigns, personalized marketing activities, event invitations, and special occasion greetings, and for being contacted by email and SMS in accordance with the Law on the Regulation of Electronic Commerce and its applicable secondary legislation.
I further consent to the sharing of these personal data with companies providing SMS and email delivery services and marketing consultancy services with which Nesiller Genetic Laboratories has contractual relationships, solely for the purposes specified above.